Last reviewed · How we verify
CSII followed by MET
CSII (continuous subcutaneous insulin infusion) followed by metformin sequentially delivers insulin and then enhances insulin sensitivity to manage blood glucose in diabetes.
CSII (continuous subcutaneous insulin infusion) followed by metformin sequentially delivers insulin and then enhances insulin sensitivity to manage blood glucose in diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | CSII followed by MET |
|---|---|
| Also known as | CSII+Met |
| Sponsor | Sun Yat-sen University |
| Drug class | Insulin + Biguanide combination regimen |
| Target | Insulin receptor (insulin); AMP-activated protein kinase pathway (metformin) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Diabetes |
| Phase | FDA-approved |
Mechanism of action
This is a treatment regimen combining continuous subcutaneous insulin infusion (an insulin pump delivering basal and bolus insulin) with subsequent metformin therapy. The approach uses intensive insulin delivery initially, followed by addition of metformin, which reduces hepatic glucose production and improves peripheral insulin sensitivity. This sequential combination aims to optimize glycemic control while potentially reducing overall insulin requirements.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Gastrointestinal disturbance (metformin)
- Injection site reactions
Key clinical trials
- Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes (PHASE4)
- Glycemic Responses to Majia Pomelos in Type 2 Diabetic Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CSII followed by MET CI brief — competitive landscape report
- CSII followed by MET updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI